RB1 and metastatic melanoma: In light of recent clinical trial data using this triple therapy against BRAFV600E-mutant melanoma, our findings demonstrating superior and prolonged durable response in PDTX models portend use of this therapeutic strategy against naïve and SOC resistant BRAFV600E-mutant metastatic melanoma coupled with pRB-Ser780 as a biomarker of response.